Suzhou Hongsen Pharmaceutical

Suzhou Hongsen Pharmaceutical is a clinical-stage biopharmaceutical company based in the Suzhou Industrial Park, China, specializing in the discovery and development of innovative small molecule therapeutics. The company primarily focuses on high-prevalence therapeutic areas, including metabolic diseases and oncology. Its lead candidate, HS-101 (hongsenliptin), is a potent and selective DPP-4 inhibitor for the treatment of Type 2 diabetes that has successfully progressed through late-stage clinical trials in China. Suzhou Hongsen leverages its internal R&D capabilities to advance a pipeline of proprietary compounds aimed at addressing significant unmet medical needs in the domestic Chinese market.